Citi initiated coverage on Bellicum Pharmaceuticals (NASDAQ: BLCM) with a Neutral rating and a price target of $36.00.Analyst Yaron Werbe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE